Redx Pharma Appoints New Chairman
News Sep 06, 2014
Frank, 57, brings a wealth of industry knowledge and highly relevant experience of oncology and anti-infectives, two of the areas of early stage drug research that have driven expansion at the company, which operates from bases in Liverpool and Alderley Park, Cheshire.
Dr Peter Jackson, co-founder and director at Redx, said: “We are delighted to welcome Frank to our board. His pharma business experience and clinical insight will make a valuable contribution to our plans for further growth and he is extremely well networked internationally. His skills and instincts are closely aligned to the breadth of our programmes in oncology and anti-infectives, and our early-stage partnering business model.”
Frank began his career as a physician before moving into the Pharma industry. He has considerable public and private company expertise, and his current roles include nonexecutive directorships with Columbia Laboratories (NASDAQ) and Actino Pharma. He is chairman of CardioRentis, Summit PLC and Xceleron and an advisor to Healthcare Royalty Partners.
His big pharma credentials include Zeneca, where he was a senior vice president, and Bayer, where he was executive vice president and head of worldwide product development.
Frank Armstrong commented, “I am delighted to be appointed Chairman of Redx at an exciting time for the company where our technology is increasingly recognized as a source of novel compounds by the Pharma industry. I am looking forward to working with the management team and Board at Redx as we build the company for greater success.”
Targeted Drug Could be Used to Treat Advanced Cancers Located Anywhere in the BodyNews
A new targeted drug could be used to treat a small number of advanced cancers no matter where they grow in the body.READ MORE
Human Malaria Parasites Grown for the First Time in Dormant FormNews
One of the biggest obstacles to eradicating malaria is a dormant form of the parasite which is resistant to most antimalarial drugs and can reawaken years later, causing disease relapse. Researchers have shown they can grow the dormant parasite in engineered human liver tissue for several weeks, allowing them to closely study how the parasite becomes dormant, what vulnerabilities it may have, and how it springs back to life.READ MORE
Bacteria Produce More Substances Than Genetics PredictedNews
Tandem mass spectrometry has revealed that Streptomyces chartreusis, an antibiotic-producing bacterium, releases more metabolites into the surrounding medium than scientists assumed based on the analysis of the genome. They might include molecules that are of interest as potential pharmaceutical agents.READ MORE